Abstract
We investigated the effects of the SGLT2 inhibitor luseogliflozin on blood and urinary glucose and body weight. Luseogliflozin 2.5 mg was administered once daily for 24 weeks to 30 outpatients with type 2 diabetes. Urinary glucose concentration, continuous glucose monitoring values, HbA1c, fasting glucose, and body weight were evaluated. Correlations with urinary glucose, subcutaneous/visceral fat mass, insulin, EPA/AA ratio, plasma free fatty acids, ghrelin, blood ketones, plasma 1,5-anhydro-D-glucitol were evaluated. Urinary glucose significantly increased from 11.1 ± 11.8 g at Week -4 to 84.5 ± 46.8 g at Week 24. HbA1c significantly declined from 7.88 ± 0.88% to 7.36 ± 1.13% at Week 24. Mean blood glucose significantly decreased from 149.6 ± 41.8 to 131.6 ± 31.1 mg/dL at Week 24. Subcutaneous and visceral fat mass was also significantly decreased, as were AST and ALT (P < 0.01). Blood urea nitrogen was significantly increased, and urate significantly decreased from 5.04 ± 1.07 to 4.53 ± 0.94 mg/dL. The homeostasis model assessment ratio remained significantly improved throughout the treatment period. Acyl ghrelin levels remained constant but des-acyl ghrelin increased significantly. Luseogliflozin monotherapy resulted in an ...Continue Reading
References
Dec 22, 1999·Nature·M KojimaK Kangawa
Nov 23, 2000·Endocrinology·Y DateM Nakazato
Feb 13, 2001·Gastroenterology·A AsakawaM Kasuga
Feb 13, 2001·Biochemical and Biophysical Research Communications·H HosodaK Kangawa
Feb 24, 2001·Nature·M NakazatoS Matsukura
Dec 18, 2002·The Journal of Cell Biology·Gianluca BaldanziAndrea Graziani
Sep 13, 2003·European Journal of Pharmacology·Ivano BedendiGiampiero Muccioli
Nov 27, 2004·Diabetes Research and Clinical Practice·Mitsuo FukushimaYutaka Seino
Dec 14, 2004·Gut·A AsakawaM Kasuga
Apr 9, 2014·Current Medical Research and Opinion·Yutaka SeinoYoshishige Samukawa
Jul 30, 2015·Journal of Diabetes Investigation·Yutaka SeinoYoshishige Samukawa
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Apr 14, 2017·Lipids in Health and Disease·Seon-Ah ChaSeung-Hyun Ko
Aug 16, 2017·Toxicology and Applied Pharmacology·Piangkwan Sa-NguanmooSiriporn C Chattipakorn
Nov 23, 2017·Obesity·Xiaoling CaiLinong Ji
Feb 7, 2018·Scientific Reports·Kumiko ShibaYoshihiro Ogawa
Mar 3, 2018·Diabetes Research and Clinical Practice·N H ChoB Malanda
Apr 17, 2018·Journal of Diabetes Investigation·Takashi SasakiMasahiro Fukuda
Jun 4, 2018·Diabetes Research and Clinical Practice·Noboru KurinamiHideaki Jinnouchi
Sep 18, 2018·Diabetes Technology & Therapeutics·Robert R HenryArie Katz
Jan 29, 2019·Journal of Diabetes Investigation·Hiroshi MiuraWataru Ogawa
Mar 20, 2019·Diabetes Care·Aino Latva-RaskuPirjo Nuutila
Apr 17, 2019·The New England Journal of Medicine·Vlado PerkovicUNKNOWN CREDENCE Trial Investigators
Jun 19, 2019·Diabetes Technology & Therapeutics·Akira KurozumiYoshiya Tanaka
Jul 14, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Tomoho NodaMasamitsu Nakazato